Quantcast

Latest Eisai Co. Ltd. Stories

2013-01-11 02:20:01

Tokyo, Jan 11, 2013 - (JCN Newswire) - Eisai Co., Ltd. announced today the preliminary results of its global Phase III study (Study FAR 131, MORAb-003-004) of farletuzumab (MORAb-003), an investigational compound under development at its U.S. subsidiary, Morphotek, Inc., in patients with platinum-sensitive epithelial ovarian cancer in first relapse.The study was a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparative study of 1,100 patients with...

2012-10-25 09:20:04

Tokyo, Oct 25, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has signed a global agreement with Brazil's Fundacao Oswaldo Cruz ("Fiocruz") aimed at collaborations to develop new medicines and vaccines for malaria and neglected tropical diseases (NTDs).Under the global agreement, Eisai and Fiocruz will identify research development collaborations targeting Eisai compounds for indications of malaria and NTDs. For the first collaboration, it has been decided to begin studies on...

2012-09-25 04:20:08

Tokyo, Sept 25, 2012 - (JCN Newswire) - Eisai Co., Ltd. and Santen Pharmaceutical Co., Ltd. announced today that they have entered into an option agreement which grants Santen rights of evaluation and first negotiation for Eisai-owned compounds in the field of ophthalmology.Under the terms of the agreement, Eisai shall grant Santen the rights to evaluate the feasibility of developing compounds disclosed by Eisai for use in the ophthalmologic field within a certain period as well as the rights...

2012-09-12 04:20:07

Tokyo, Sept 12, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a partnership agreement to supply the Sabin Vaccine Institute (Headquarters: Washington D.C., President: Dr. Peter Hotez, "Sabin") with E6020, an in-house developed adjuvant that enhances the immune effects of vaccines, as well as all relevant information pertaining to the compound free of charge, to support the development of vaccines for two neglected tropical diseases (NTDs) - Chagas disease...

2012-09-12 04:20:02

Tokyo, Sept 12, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch Crystal Veil(R) alpha (classified as miscellaneous goods), a drug-free topical nasal gel that utilizes positively charged ions to help block viruses from entering the body through the nose, on Tuesday, September 18.Crystal Veil alpha is a positively-charged gel that helps prevent virus particles, which are even smaller than pollen, from entering through the nose. It is the third product in the Crystal...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.